抗HIV治療ガイドライン（2024年3月発行）

VIII抗HIV薬の作用機序と薬物動態

文献

  1. Clerq E. Anti-HIV drugs: 25 compounds approved within 25 years after the discovery of HIV. Int J Antimicrob Agents. 33: 307-20. 2009.
  2. リカムビス®水懸筋注インタビューフォーム（2023年9月改訂（第3版），ヤンセンファーマ株式会社．
  3. Pommier Y, Johnson AA, Marchand C. Integrase inhibitors to treat HIV/AIDS. Nat. Rev. Drug Discov. 4:236-48.2005.
  4. Engelman A, Mizuuchi K, Craigie R. HIV-1 DNA integration: mechanism of viral DNA cleavage and DNA strand transfer. Cell. 67:1211-21. 1991.
  5. ボカブリア錠，ボカブリア水懸筋注インタビューフォーム（2023年7月改訂（第3版），ヴィーブヘルスケア株式会社．
  6. シーエルセントリ®錠インタビューフォーム（2022年9月改訂（第9版），ヴィーブヘルスケア株式会社．
  7. Link JO, Rhee MS, Tse WC, et al. Clinical targeting of HIV capsid protein with a long-acting small molecule. Nature. 584(7822):614-618. 2020.
  8. Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents with HIV (米国DHHS, Feb 27,2024).
    https://clinicalinfo.hiv.gov/en/guidelines/hiv-clinical-guidelines-adult-and-adolescent-arv/whats-new
  9. Han K, Baker M, Lovern M, et al. Population pharmacokinetics of cabotegravir following administration of oral tablet and long-acting intramuscular injection in adult HIV-1-infected and uninfected subjects. Br J Clin Pharmacol. Oct;88(10):4607-4622, 2022.
  10. Khalilieh SG, Yee KL, Sanchez RI, et al. Multiple Doses of Rifabutin Reduce Exposure of Doravirine in Healthy Subjects. J Clin Pharmacol. 58(8):1044–52. 2018.
  11. Kassahun K, McIntosh I, Cui D, et al. Metabolism and disposition in humans of raltegravir (MK-0518), an anti-AIDS drug targeting the human immunodeficiency virus 1 integrase enzyme. Drug Metab. Dispos. 35: 1657-63. 2007.
  12. Ramanathan S, Mathias AA, German P, et al. Clinical pharmacokinetic and pharmacodynamic profile of the HIV integrase inhibitor elvitegravir. Journal Clin Pharmacokinet. 50:229-44. 2011.
  13. Hazuda D, Iwamoto M, Wenning L. Emerging pharmacology: inhibitors of human immunodeficiency virus integration. Annu. Rev. Pharmacol. Toxicol. 49:377–394. 2009.
  14. European AIDS Clinical Society (EACS) Guidelines. Version 12.0-October 2023.
    https://www.eacsociety.org/guidelines/eacs-guidelines/
  15. 増田純一, 菊地 正；日本医療研究開発機構 エイズ対策実用化研究事業「国内流行HIV及びその薬剤耐性株の長期的動向把握に関する研究」班: 抗HIV薬血中濃度測定マニュアル第3版.
  16. Rodríguez-Nóvoa S, Labarga P, Pablo D, et al. Impairment in kidney tubular function in patients receiving tenofovir is associated with higher tenofovir plasma concentrations. AIDS. 24:1064-6, 2010.
  17. Cutrell AG, Schapiro JM, Perno CF, et al. Exploring predictors of HIV-1 virologic failure to long-acting cabotegravir and rilpivirine: a multivariable analysis. AIDS. 35(9):1333-1342. 2021.
  18. Orkin C, Schapiro JM, Perno CF, et al. Expanded Multivariable Models to Assist Patient Selection for Long-Acting Cabotegravir + Rilpivirine Treatment: Clinical Utility of a Combination of Patient, Drug Concentration, and Viral Factors Associated With Virologic Failure. Clin Infect Dis. 77(10):1423-1431. 2023.
  19. Wenning L, Hwang1 E, Nguyen1 B-Y, et al. Pharmacokinetic/Pharmacodynamic (PK/PD) Analyses for Raltegravir (RAL) in Phase III Studies in Treatment Experienced HIV-Infected Patients Following 48 Weeks of Treatment [abstract #H-4054]. 48th Annual ICAAC/IDSA 46th Annual Meeting; 2008 October 25-28. Washington DC, USA.
  20. Hluhanich R, Kinkade A, Margot NA, et al. HIV integrase inhibitors do not exert a post-antibiotic effect despite slow dissociation from IN-DNA complexes in vitro [abstract H930]. 49th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2009 September 12-15; San Francisco, California.
  21. Yagura H, Watanabe D, Nakauchi T, et al. Effect of dolutegravir plasma concentration on central nervous system side effects. Conference on Retroviruses and Opportunistic Infections; 2017 February 13-16. Seattle, USA.
  22. The Department of Health and Human Services : Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents, revised on May 1, 2014.
  23. Food and Drug Administration (FDA). Prezista (package insert). 2010.
    https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/021976s016lbl.pdf
  24. 矢倉裕輝, 櫛田宏幸, 冨島公介ら. 当院におけるリルピビリン塩酸塩の使用成績　第2報. 2014年 第28回日本エイズ学会学術集会・総会（大阪）, 抄録番号O4-022
  25. 吉野宗宏, 矢倉裕輝，櫛田宏幸ら. 当院における1 日1 回投与ダルナビル / リトナビルの使用成績, 日本エイズ学会誌, 14:141-5, 2012.
  26. Yagura H, Watanabe D, Ashida M, et al. Correlation between UGT1A1 polymorphisms and raltegravir plasma trough concentrations in Japanese HIV-1-infected patients. J Infect Chemother. 21:713-7. 2015.
  27. 矢倉裕輝, 中内崇夫, 冨島公介ら. 日本人HIV-1感染症症例におけるエルビテグラビルおよびコビシスタットの血漿トラフ濃度に関する検討, 第30回日本エイズ学会学術集会・総会（鹿児島）, 抄録番号P-038.
  28. Yagura H, Watanabe D, Kushida H, et al. Impact of UGT1A1 gene polymorphisms on plasma dolutegravir trough concentrations and neuropsychiatric adverse events in Japanese individuals infected with HIV-1. BMC Infect Dis. 17:622. 2017.
  29. 矢倉裕輝, 中内崇夫, 櫛田宏幸ら. 日本人HIV-1感染者におけるビクテグラビルの血漿中濃度に関する検討 第1報. 2020年 第34回日本エイズ学会学術集会・総会（WEB）, 抄録番号O-C7-1.
  30. 矢倉裕輝, 中内崇夫, 櫛田宏幸ら. 日本人HIV-1感染者におけるドラビリンの血漿中濃度に関する検討 第1報. 2021年 第35回日本エイズ学会学術集会・総会, 抄録番号O-C07-01.
  31. 矢倉裕輝, 櫛田宏幸, 廣田和之ら. カボテグラビル・リルピビリンの持効性注射製剤の血中濃度に関する検討 第１報. 2023年 第37回日本エイズ学会学術集会・総会, 抄録番号O-8-5.

PAGE TOP